Study enhances antimicrobial activity of modified peptides in resistant pathogens, suggesting novel treatment pathways.
The widespread emergence of antibiotic-resistant pathogens poses a significant global health challenge and underscores the need for novel approaches to accelerate antimicrobial discovery. Antimicrobial peptides (AMPs) have gained attention as promising candidates due to their broad-spectrum activity, including efficacy against multidrug-resistant bacterial strains. SAJO-2, an antimicrobial peptide developed by Sarojini and colleagues, features a tryptophan zipper-like motif incorporating a central d-Phe-2-Abz unit, where 2-Abz functions as a conformationally constrained β-turn-inducing peptidomimetic scaffold. Modification of SAJO-2 in prior joint work from our groups through differential fluorination enhanced its antimicrobial potency; however, it also increased susceptibility to enzymatic digestion by β-trypsin. To address this limitation, the current research focuses on improving the overall efficacy of SAJO-2 through the incorporation of D-amino acids, beta backbone modifications, and a bulky pentafluorinated amino acid residue. All modified peptides exhibit resistance to enzymatic degradation, while antimicrobial activity was retained to differing degrees across organisms.
No takes yet. Share an insight, caveat, or question.
Rathessan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: